Historical and projected public spending on drugs for rare diseases in Canada between 2010 and 2025

Abstract Objective Rare diseases are life-threatening, debilitating, or serious chronic conditions that affect < 50/100,000 people. Canadians can only access approximately 60% of drugs for rare diseases (DRDs), which is partially related to high per-patient costs and payers’ affordability concern...

Full description

Bibliographic Details
Published in:	Orphanet Journal of Rare Diseases
Main Authors:	Richard Lech, Gideon Chow, Kamalpreet Mann, Patrick Mott, Christine Malmberg, Lindy Forte
Format:	Article
Language:	English
Published:	BMC 2022-10-01
Subjects:	Canada Drugs for rare diseases Orphan drugs Drug funding Orphan diseases Patient access
Online Access:	https://doi.org/10.1186/s13023-022-02534-z

Similar Items

Analysis of patient access to orphan drugs in Turkey
by: Güvenç Koçkaya, et al.
Published: (2021-02-01)

Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union
by: Bander Balkhi, et al.
Published: (2023-09-01)

Practice of the Qualification and Recognition for Orphan Drugs in the World and its Inspiration
by: ZHU Xiaohong, et al.
Published: (2022-07-01)

Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada
by: Fernanda Naomi Inagaki Nagase, et al.
Published: (2019-06-01)

Visual Research of Global Orphan Drug from a Bibliometric Perspective
by: Wen X, et al.
Published: (2025-05-01)

Strategic discussion on funding and access to therapies targeting rare diseases in Spain: an expert consensus paper
by: N. Zozaya, et al.
Published: (2023-02-01)

Current Problems in Provision of Orphan Drugs and Ways to Solve Them
by: Alexei S. Kolbin, et al.
Published: (2016-09-01)

Current Status of Drug Development and Implementation for Diseases Included in the Second Catalog of Rare Diseases
by: LI Kexin, et al.
Published: (2023-10-01)

Overview and Analysis of Rare Disease Drugs Approved for Market in China, the United States, the European Union, and Japan in 2023
by: WANG Shaohong, et al.
Published: (2024-04-01)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
by: ZHANG Shan, et al.
Published: (2023-04-01)

Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review
by: Qin Xiang Ng, et al.
Published: (2024-06-01)

Crowd Funding for Orphan Drugs: The Case of Baby Pia
by: Wim Pinxten
Published: (2021-12-01)

Development of orphan drugs for rare diseases
by: Han-Wook Yoo
Published: (2024-07-01)

What is the awareness of rare diseases among medical students? A survey in Bulgaria
by: Eleonora Hristova-Atanasova, et al.
Published: (2023-07-01)

Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01)

VITAL MEDICINES NOT AVAILABLE: NATIONAL AND INTERNATIONAL REGULATION ANALYSIS, UPDATE PROPOSAL OF NATIONAL LIST
by: Gloria A. SANDOVAL, et al.
Published: (2009-02-01)

Features of intellectual property protection mechanisms on the example of orphan drugs circulation
by: D. S. Yurochkin, et al.
Published: (2022-01-01)

Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen
by: Viviana Giannuzzi, et al.
Published: (2017-04-01)

Examining Why the Canadian Federal Government Placed an Orphan Drug Strategy on Their Decision Agenda Now
by: Mark Gary Embrett
Published: (2014-02-01)

Utilization and affordability of health insurance coverage for rare disease drugs in a first-tier city in Northeast China from 2018 to 2021: a study based on the health insurance claims database
by: Yaqun Wang, et al.
Published: (2024-07-01)

Clinical trials and the importance of biobanks in rare diseases
by: Nežić Lana, et al.
Published: (2018-01-01)

Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs—a Systematic Literature Review. Next Steps in Methodology Development?
by: Aleksandra Baran-Kooiker, et al.
Published: (2018-10-01)

Clinical genetics and public policies: how should rare diseases be managed?
by: Ida Schwartz, et al.
Published: (2014-07-01)

Patient access to orphan drugs in France
by: Marion Bourdoncle, et al.
Published: (2019-02-01)

Current Status and Challenges of Guarantee for Rare Disease Drugs
by: ZUO Wei, et al.
Published: (2024-04-01)

Patient organization involvement and the challenge of securing access to treatments for rare diseases: report of a policy engagement workshop
by: Koichi Mikami, et al.
Published: (2017-09-01)

Determinants of orphan drugs prices in France: a regression analysis
by: Daria Korchagina, et al.
Published: (2017-04-01)

Orphan diseases and associated problems
by: V. A. Shashel, et al.
Published: (2021-07-01)

Quality and quantity of data used by Health Canada in approving new drugs
by: Joel Lexchin, et al.
Published: (2023-11-01)

Study on Drug List and Accessibility of Rare Diseases Based on the China′s Second List of Rare Diseases
by: LIU Qingyang, et al.
Published: (2024-04-01)

Research of Accessibility of Rare Disease Drugs Based on the China's First List of Rare Diseases
by: LIU Qingyang, et al.
Published: (2023-11-01)

REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS
by: Andrey Vladislavovich Pavlysh, et al.
Published: (2015-09-01)

A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01)

Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)

Time to market evaluation for new chemical entities in Italy: a critical analysis of the period 2018-2024
by: Alessandro Tedesco, et al.
Published: (2025-05-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Clinical and non-clinical aspects of reimbursement policy for orphan drugs in selected European countries
by: Szczepan Jakubowski, et al.
Published: (2024-11-01)

Orphan drug policy analysis in China
by: Meilin Liu, et al.
Published: (2024-06-01)

Elements for Ethic Review of Clinical Trials for Rare Disease Drugs
by: BAI Hua
Published: (2024-04-01)

Pharmacotherapeutic Patterns and Patients’ Access to Pharmacotherapy for Some Rare Diseases in Bulgaria – A Pilot Comparative Study
by: Maria Kamusheva, et al.
Published: (2021-07-01)